<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2402221766
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MOVEN 15MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MELOXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Arab Pharmaceutical Manufacturing PSC Sult" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Arab Pharmaceutical Manufacturing PSC Sult
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            THE ARAB PHARMACEUTICAL MANUFACTURING PSC (SAHAB)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Meloxicam belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs) used for the treatment of pain and to reduce inflammatory conditions in muscles and joints.</p><p>&nbsp;</p><p><strong>Meloxicam have been approved for:</strong></p><ul><li>The short-term symptomatic treatment of osteoarthrosis (joint disease where the cartilage is lost)</li><li>The long-term symptomatic treatment of pain in connection with rheumatoid arthritis</li><li>The long-term symptomatic treatment of a similar condition called ankylosing spondylitis (inflammation of the spine).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Moven:</strong></p><ul><li>During the last trimester of pregnancy</li><li>If you are allergic (hypersensitive) to meloxicam or any of the other ingredients of Moven</li><li>If you are allergic to acetylsalicylic acid (e.g. aspirin) or other non-steroidal anti-inflammatory drugs (NSAID). You must not use meloxicam if you have previously had symptoms of asthma, nasal polyps, swelling in the skin or mucous membranes (oedema) or hives (urticaria) following treatment with acetylsalicyclic acid or other anti-inflammatory medicines</li><li>If you have, or have had recurrent stomach or gut ulcers or oesphagitis (inflammation of the gullet), gastritis (inflammation of the stomach)&nbsp;</li><li>If you have bleeding disorder or have ever suffered from bleeding in the stomach or bowel (gastrointestinal bleeding), or bleeding in the brain (cerebrovascular bleeding)</li><li>If you have severe liver problems</li><li>If you have severe kidney failure and are not receiving dialysis</li><li>If you suffer from severe heart failure.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Take special care with Moven:</p><ul><li>If you have previously had inflammation of the oesophagus (oesophagitis); inflammation of the stomach lining (gastritis) and/or stomach ulcers</li><li>If you have a history of problems with your stomach or gut (such as Crohn&rsquo;s disease or ulcerative colitis)</li><li>If you are elderly (because of increased side effects)</li><li>If you have recently undergone major surgery</li><li>If you have liver, kidney or heart problems</li><li>If you are suffering from or have a history of asthma</li><li>If you have an IUD (intra-uterine device e.g. coil) fitted for contraception; the coil may not be as effective</li><li>If you notice blood in your faeces (stools)</li><li>If you notice any skin reaction</li><li>If you have to take a blood or urine test, always mention that you are taking Moven</li><li>If you are trying to become pregnant or undergoing investigations of fertility</li><li>If you suffer from an infectious disease, this medicinal product may mask symptoms.</li></ul><p>&nbsp;</p><p>Medicines such as meloxicam may be associated with&nbsp;a small increased risk of heart attack (&ldquo;myocardial infarction&rdquo;) or stroke. Any risk is more likely with high doses and prolonged treatment. Do not exceed the recommended dose or duration of treatment.</p><p>&nbsp;</p><p>If you have heart problems, previous stroke or think that you might be at risk of these conditions (for example if you have a high blood pressure, diabetes or high cholesterol or are a smoker) you should discuss your treatment with your doctor or pharmacist.</p><p>&nbsp;</p><p>Potentially life-threatening skin rashes (Stevens- Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of meloxicam, appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes).</p><p>&nbsp;</p><p>These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment.</p><p>&nbsp;</p><p>If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of meloxicam, you must not be re-started on meloxicam at any time. If you develop a rash or these skin symptoms, stop taking Moven, seek urgent advice from a doctor and tell him that you are taking this medicine.</p><p>&nbsp;</p><p><strong>Other medicines and Moven</strong></p><p>The following medicines can affect or be affected by Moven:</p><ul><li>Anticoagulants, to stop your blood clotting, such as warfarin, heparin and ticlopidine</li><li>Other non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin</li><li>Lithium (for mental illness)</li><li>Methotrexate (for psoriasis and some cancers)</li><li>Thrombolytics (for heart conditions to dissolve blood clots)</li><li>Cholestyramine (for reducing cholesterol)</li><li>Ciclosporin (an immunosuppressant)</li><li>Diuretics (water tablets)</li><li>Medicines to treat high blood pressure such as atenolol and enalapril</li><li>Corticosteroids (for asthma, inflammation and after organ transplant surgery)</li><li>Selective serotonin-reuptake inhibitors (for depression)</li><li>Intrauterine contraceptive devices (contraceptive coils)</li></ul><p>&nbsp;</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Moven with food and drink </strong></p><p>Moven should be swallowed with water during a meal.</p><p>&nbsp;</p><p><strong>Pregnancy and breast feeding </strong></p><p>Ask your doctor before taking meloxicam during the first two trimesters of pregnancy. Because of an increased risk of complications for mother and child, do not take meloxicam during the last trimester of pregnancy. The use of meloxicam is not recommended while breast-feeding. Ask your doctor before taking meloxicam if you are breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>meloxicam may cause side effects that may affect a person&#39;s ability to drive and use machinery. Examples of side effects include visual disturbances, drowsiness or dizziness. If you suffer from any of these side effects it is advisable to refrain from driving or using machinery.</p><p>&nbsp;</p><p><strong>Moven contains lactose and sodium</strong></p><p>Moven contains lactose. Each capsule of Moven 7.5 mg and 15 mg Capsules contains 101.4 mg or 86 mg lactose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p>Moven contains sodium. Each capsule of Moven 7.5 mg and 15 mg Capsules contains 3.2 mg or 6.4 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Moven exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Your doctor will give you the lowest possible dose, for the shortest length of time, to treat your symptoms. If your condition does not get better or you suffer from any side effects, tell your doctor. Your doctor should monitor your condition and treatment.</p><p>&nbsp;</p><p><strong>Dosage </strong></p><p><em>Treatment of osteoarthrosis:</em></p><p>The recommended dose is 7.5 mg once daily. This may be increased by your doctor to 15 mg once daily if the effect is too weak.</p><p>&nbsp;</p><p><em>Treatment of pain from rheumatoid arthritis and ankylosing spondylitis:</em></p><p>The recommended dose is 15 mg once daily. Your doctor may reduce your dose to 7.5 mg a day if your symptoms improve.</p><p>&nbsp;</p><p>Never exceed a dose of 15 mg a day.</p><p>&nbsp;</p><p><em>Kidney and liver impairment:</em></p><p>In dialysis patients with severe kidney failure, dosage should not exceed one capsule of 7.5 mg a day. Patients with kidney or liver problems that are not severe can be given the doses as stated above. Meloxicam are not recommended for use for patients with severe kidney failure who are not receiving dialysis.</p><p>&nbsp;</p><p><em>Elderly:</em></p><p>If you are elderly your doctor may recommend a lower dose. The recommended dose for treatment of rheumatoid arthritis and ankylosing spondylitis is 7.5 mg once daily.</p><p>&nbsp;</p><p><em>Children:</em></p><p>Children under the age of 16 years should not take Moven.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Take Moven orally as a single dose with water and together with a meal.</p><p>&nbsp;</p><p><strong>If you take more Moven than you should </strong></p><p>Contact your doctor or local emergency ward. Take this leaflet and any capsules you still have with you. Symptoms of overdose include increased blood pressure, kidney failure, liver dysfunction, coma, heart problems, lethargy, drowsiness, feeling and being sick and stomach pains.</p><p>&nbsp;</p><p><strong>If you forget to take Moven</strong></p><p>If you forget to take a dose, take it as soon as you remember it unless it is nearly time for your next dose. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Moven</strong></p><p>Stopping your medicine before finishing the course of treatment may cause your pain or inflammation to get worse. It is important not to stop taking your medicine without discussion with your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, meloxicam can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following side effects have been reported:</p><p><strong>Common: affecting fewer than 1 in 10 people</strong></p><ul><li>Anaemia (looking pale and feeling abnormally tired)</li><li>Dizziness (light-headedness)</li><li>Headache</li><li>Indigestion</li><li>Nausea (feeling sick)</li><li>Vomiting</li><li>Stomach pain</li><li>Constipation</li><li>Wind</li><li>Diarrhoea</li><li>Intense itching</li><li>Rash</li><li>Swelling especially of the lower limbs.</li></ul><p>&nbsp;</p><p><strong>Uncommon: affecting fewer than 1 in 100 people</strong></p><ul><li>Blood changes</li><li>Vertigo</li><li>Ringing in the ears</li><li>Drowsiness</li><li>Palpitations</li><li>Increased blood pressure</li><li>Feeling flushed</li><li>Blood in your faeces (stools)</li><li>Stomach ulcers</li><li>Inflammation of the oesophagus (food pipe) symptoms include heartburn and a difficulty swallowing</li><li>Sore mouth or mouth ulcers</li><li>Changes to kidney or liver function tests</li></ul><p>&nbsp;</p><p><strong>Rare: affecting fewer than 1 in 1,000 people</strong></p><ul><li>Severe allergic reaction</li><li>Mood disorders</li><li>Difficulty sleeping (insomnia)</li><li>Nightmares</li><li>Feeling confused</li><li>Eyesight problems such as blurred vision</li><li>Asthma attacks</li><li>Pain due to tearing of the stomach or gut wall</li><li>Inflamed stomach or colon</li><li>Hepatitis (liver problems)</li><li>Severe skin reactions (such as rash, fever and blistering)</li><li>Skin sensitivity to light</li><li>Kidney failure</li><li>Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (see section 2).</li></ul><p>&nbsp;</p><p><strong>Very rare: affecting fewer than 1 in 10,000 people</strong></p><ul><li>Itchy swollen skin</li><li>Red, itchy spots similar to measles</li></ul><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data.</strong></p><ul><li>Skin sensitivity to light</li></ul><p>&nbsp;</p><p>Stomach ulcers may occur. These may bleed into the gut (causing offensive, tar-coloured stools), rarely these ulcers may perforate causing a hole in the wall of the bowel.</p><p>&nbsp;</p><p>These can occur at any time and are especially important in the elderly and very rarely have been fatal. If any of these symptoms occur you should contact your doctor immediately.</p><p>&nbsp;</p><p>Rarely, serious allergic reactions such as anaphylactic shock can occur. Symptoms include swelling of the face, lips, tongue and throat which can result in breathing difficulties. If you think you are having an allergic reaction or you feel unwell stop the treatment and seek medical advice immediately.</p><p>&nbsp;</p><p>In rare cases, meloxicam can affect the white blood cells which can weaken your defense against infection. If you contract an infection with symptoms such as fever, with rapid deterioration in general condition, or fever with local infection symptoms such as pain in the neck, throat, mouth or difficulty passing urine, you must contact your doctor immediately for a blood test to rule out a shortage of white blood cells (agranulocytosis).</p><p>&nbsp;</p><p>Medicines such as meloxicam may be associated with a small increased risk of heart attack (&ldquo;myocardial infarction&rdquo;) or stroke.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a dry place below 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. Date. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist on how to dispose of medicines no longer required. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is meloxicam.</p><p>&nbsp;</p><p>Each capsule of Moven 7.5 mg and 15 mg Capsules contains 7.5 mg or 15 mg meloxicam; respectively.</p><p>&nbsp;</p><p>The other ingredients are lactose, trisodium citrate, maize starch, colloidal silicone dioxide and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Moven 7.5 mg Capsules are size (3) opaque green-off white polished capsules printed with black logo “141” on the cap and ”AP” on the body, filled with yellow powder free from visible contaminants in polyvinyl chloride/polyvinylidene chloride- aluminum blisters.

Moven 15 mg Capsules are size (3) opaque blue-buff polished capsules printed with black logo “142” on the cap and ”AP” on the body, filled with yellow powder free from visible contaminants in polyvinyl chloride/polyvinylidene chloride- aluminum blisters.

Pack size: 10 or 30 Capsules.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC<br />P.O. Box 42<br />Sult, Jordan<br />Tel: + (962-5)3492200<br />Fax: + (962-5)3492203</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 06/2021; version number SA2.0. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي ميلوكسيكام إلى مجموعة الأدوية غير الستيرويدية المضادة للالتهاب التي تستخدم لعلاج الألم وتخفيف حالات الالتهاب في العضلات والمفاصل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثبت ميلوكسيكام فعاليته في:</strong></p><ul dir="rtl"><li>العلاج قصير المدى لأعراض الفصال العظمي (مرض المفاصل الذي يحدث فيه تآكل للغضروف)</li><li>العلاج طويل المدى لأعراض الألم المرتبط بالتهاب المفاصل الروماتويدي</li><li>العلاج طويل المدى لأعراض حالة مرضية مماثلة تسمى التهاب الفقار اللاصق (التهاب النخاع).</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول موڤن:</strong></p><ul dir="rtl"><li>خلال الثلث الأخير من الحمل</li><li>إذا كنت تعاني من حساسية (فرط الحساسية) لميلوكسيكام أو لأي من المكونات الأخرى المستخدمة في موڤن</li><li>إذا كنت تعاني من حساسية لحمض الأسيتيل ساليسيليك (مثل الأسبرين) أو غيره من الأدوية غير الستيرويدية المضادة للالتهاب. يجب أن لا يتستخدم ميلوكسيكام إذا سبق وأن عانيت من أعراض الربو، السلائل الأنفية، تورم في الجلد أو الأغشية المخاطية (وذمة) أو الشرى بعد العلاج بحمض الأسيتيل ساليسيليك أو غيره من الأدوية المضادة للالتهاب</li><li>إذا كنت تعاني، أو عانيت سابقاً، من تقرحات متكررة في المعدة أو الأمعاء أو التهاب المريء، التهاب المعدة&nbsp;</li><li>إذا كنت تعاني من اعتلال نزفي أو سبق وأن عانيت من نزيف في المعدة أو الأمعاء (النزف الهضمي)، أو من نزيف في المخ (نزف دماغي وعائي)</li><li>إذا كنت تعاني من مشاكل شديدة في الكبد</li><li>إذا كنت تعاني من فشل كلوي شديد دون غسيل للكلى</li><li>إذا كنت تعاني من فشل شديد في القلب.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">اتبع عناية خاصة مع<strong> </strong>موڤن<strong>:</strong></p><ul dir="rtl"><li>إذا سبق لك أن أصبت بالتهاب المريء، التهاب بطانة المعدة و/أو تقرحات المعدة</li><li>إذا كان لك تاريخ مع مشاكل في المعدة أو الأمعاء (مثل داء كرون أو التهاب القولون التقرحي)</li><li>إذا كنت من كبار السن (بسبب زيادة الآثار الجانبية)</li><li>إذا كنت قد قمت مؤخراً بجراحة كبيرة</li><li>إذا كنت تعاني من مشاكل في الكبد، الكلى أو القلب</li><li>إذا كنت تعاني من الربو أو كان لديك تاريخ من الإصابة به</li><li>إذا كان لديكِ جهاز داخل الرحم (مثل اللولب) لمنع الحمل؛ قد لا يكون اللولب فعالاً</li><li>إذا لاحظت وجود دم في البراز</li><li>إذا لاحظت وجود أي تفاعل جلدي</li><li>إذا احتجت إلى إجراء تحليل دم أو بول، أخبر الطبيب دائماً بأنك تتناول موڤن</li><li>إذا كنت تخططين لأن تصبحي حاملاً أو تخضعين لتحاليل الخصوبة</li><li>إذا كنت تعاني من مرض معدٍ، قد يخفي هذا الدواء الأعراض.<strong>&nbsp;</strong></li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن ترتبط بعض الأدوية مثل ميلوكسيكام بزيادة بسيطة في احتمالية حدوث نوبة قلبية (&quot;احتشاء عضلة القلب&quot;) أو سكتة دماغية. أي خطر تكون احتماليته أكبر مع ارتفاع الجرعات وتمديد فترة العلاج. لا تتجاوز الجرعة الموصى بها أو مدة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من مشاكل في القلب، سكتة دماغية سابقة أو تعتقد أنك معرض للإصابة بهذه الحالات (على سبيل المثال إذا كنت تعاني من ارتفاع ضغط الدم، السكري أو ارتفاع الكوليسترول أو مدخن) فيجب أن تستشير الطبيب أو الصيدلي حول العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن وجود طفح جلدي يمكن أن يكون مهدد للحياة (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي) عند استخدام ميلوكسيكام، والتي تظهر في البداية على هيئة بقع صغيرة تميل إلى اللون الأحمر أو لطخات دائرية مع نفطات مركزية على البدن. تشمل العلامات الإضافية التي يمكن البحث عنها التقرحات في الفم، الحلق، الأنف، الأعضاء التناسلية، والتهاب الملتحمة (احمرار وتورم العينين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">حالات الطفح الجلدي هذه التي يمكن أن تكون مهددة للحياة عادة ما تكون مصحوبة بأعراض تشبه الأنفلونزا. قد يتفاقم الطفح الجلدي ليصل إلى انتشار النفطات أو تقشر الجلد. أعلى خطر لحدوث تفاعلات جلدية خطيرة يكون خلال الأسابيع الأولى من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهرت عليك أعراض متلازمة ستيفنز جونسون أو تقشر الأنسجة المتموتة البشروية التسممي مع استخدام ميلوكسيكام، فيجب ألا تعود لاستخدام ميلوكسيكام في أي وقت. إذا ظهرت عليك أعراض الطفح أو هذه الأعراض الجلدية، فتوقف عن تناول موڤن، واطلب المشورة العاجلة من طبيب وأخبره أنك تتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وموڤن</strong></p><p dir="RTL">يمكن أن تؤثر الأدوية التالية أو تتأثر بموڤن:</p><ul dir="rtl"><li>مضادات التخثر، لإيقاف تخثر الدم بالجسم، مثل الوارفارين، الهيبارين والتيكلوبيدين</li><li>الأدوية غير الستيرويدية المضادة للالتهاب مثل الأسبرين</li><li>الليثيوم (للأمراض النفسية)</li><li>الميثوتركسات (للصدفية وبعض أنواع السرطان)</li><li>الأدوية المساعدة على انحلال التخثر (لحالات القلب لإذابة جلطات الدم)</li><li>الكوليسترامين (لخفض الكوليسترول)</li><li>السيكلوسبورين (كابت مناعة)</li><li>مدرات البول (أقراص المياه)</li><li>أدوية علاج ارتفاع ضغط الدم مثل أتينولول وإنالابريل</li><li>الستيرويدات القشرية (للربو، الالتهابات وبعد جراحة زرع الأعضاء)</li><li>مثبطات استرجاع السيروتونين الانتقائية (لعلاج الاكتئاب)</li><li>وسائل منع الحمل داخل الرحم (اللولب الرحمي)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى، بما في ذلك الأدوية التي تُصرف دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موڤن مع الطعام والشراب </strong></p><p dir="RTL">يجب بلع موڤن مع الماء أثناء تناول وجبة طعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">استشيري طبيبكِ قبل تناول ميلوكسيكام خلال أول ثلثين من الحمل. لا تتناولي ميلوكسيكام خلال الثلث الأخير من الحمل بسبب زيادة خطر حدوث مضاعفات على الأم والطفل. لا يوصى باستخدام ميلوكسيكام أثناء الرضاعة. استشيري طبيبك قبل تناول ميلوكسيكام إذا كنتِ مرضعاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يتسبب ميلوكسيكام في حدوث آثار جانبية قد تؤثر على قدرة الشخص على القيادة واستخدام الآلات. تشمل أمثلة الآثار الجانبية الاضطرابات البصرية، النعاس أو الدوخة. إذا عانيت من أي من هذه الآثار الجانبية، يُوصى بعدم القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي موڤن على </strong><strong>ال</strong><strong>لاكتوز والصوديوم</strong></p><p dir="RTL">يحتوي موڤن على اللاكتوز. تحتوي كل كبسولة من موڤن ٧.٥&nbsp;ملغم و١٥ ملغم كبسولات على ١٠١.٤ ملغم أو ٨٦ ملغم لاكتوز؛ على التوالي. إذا أخبرك طبيبك أن لديك عدم تحمل لبعض أنواع السكريات، تواصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي موڤن على الصوديوم. تحتوي كل كبسولة من موڤن ٧.٥ ملغم و١٥ ملغم كبسولات على ٣.٢ ملغم أو ٦.٤ ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من ١ ملمول صوديوم (٢٣ ملغم) لكل كبسولة، بذلك يمكن اعتباره بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول موڤن كما أخبرك طبيبك. تأكد من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيصف لك طبيبك أقل جرعة ممكنة، لأقصر مدة، لعلاج أعراضك. إذا لم تتحسن حالتك أو كنت تعاني من أي آثار جانبية، أخبر طبيبك. ينبغي أن يتابع طبيبك حالتك وعلاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة </strong></p><p dir="RTL"><em>علاج الفصال العظمي:</em></p><p dir="RTL">الجرعة الموصى بها هي ٧.٥ ملغم مرة واحدة يومياً. قد يرفع طبيبك الجرعة إلى ١٥ ملغم مرة يومياً إذا كان المفعول ضعيفاً للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>علاج ألم التهاب المفاصل الروماتويدي والتهاب الفقار اللاصق:</em></p><p dir="RTL">الجرعة الموصى بها هي ١٥ ملغم مرة واحدة يومياً. قد يخفض الطبيب جرعتك إلى ٧.٥ ملغم في اليوم إذا تحسنت الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتجاوز جرعة ١٥ ملغم في اليوم مطلقاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>قصور الكلى والكبد:</em></p><p dir="RTL">ينبغي ألا تتجاوز الجرعة كبسولة واحدة من ٧.٥ ملغم يومياً لدى مرضى الفشل الكلوي الشديد الذين يغسلون الكلى. يمكن إعطاء الجرعات للمرضى الذين يعانون من مشاكل غير شديدة في الكلى أو الكبد كما هو موضح بالأعلى. لا يوصى بتناول ميلوكسيكام لمرضى الفشل الكلوي الشديد ممن لا يقومون بغسيل الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>كبار السن:</em></p><p dir="RTL">قد يوصي الطبيب بجرعة أقل إذا كنت من كبار السن. الجرعة الموصى بها لعلاج التهاب المفاصل الروماتويدي والتهاب الفقار اللاصق هي ٧.٥ ملغم مرة واحدة يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال:</em></p><p dir="RTL">يجب أن لا يتناول الأطفال موڤن دون سن ١٦ عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">تناول موڤن عن طريق الفم كجرعة واحدة مع الماء وأثناء تناول وجبة طعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت موڤن </strong><strong>أكثر من اللازم</strong></p><p dir="RTL">تواصل مع طبيبك أو قسم الطوارئ المحلي. خذ معك هذه النشرة وأي كبسولات لا تزال معك. تشمل أعراض فرط الجرعة ارتفاع ضغط الدم، الفشل الكلوي، خلل في وظائف الكبد، غيبوبة، مشاكل في القلب، خمول، نعاس، غثيان وقيء وآلام بالمعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول موڤن</strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناولها فور تذكرها إلا إذا كان وقت الجرعة التالية قريب. لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول موڤن</strong></p><p dir="RTL">قد يتسبب وقف تناول الدواء قبل انتهاء مدة العلاج في تدهور الألم أو الالتهاب. ينبغي ألا تتوقف عن تناول هذا الدواء دون مناقشة طبيبك.</p><p dir="RTL">&nbsp;</p><p>إذا كان لديك أية أسئلة إضافية حول استخدام هذا المستحضر، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب ميلوكسيكام آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية:</p><p dir="RTL"><strong>شائعة: قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص</strong></p><ul dir="rtl"><li>فقر الدم (شحوب وشعور بالتعب بشكل غير طبيعي)</li><li>دوخة (دوار)</li><li>صداع</li><li>عسر الهضم</li><li>الغثيان</li><li>القيء</li><li>ألم بالمعدة</li><li>إمساك</li><li>ريح</li><li>إسهال</li><li>حكة شديدة</li><li>طفح</li><li>تورم وخاصة في الأطراف السفلية.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص</strong></p><ul dir="rtl"><li>تغيرات في الدم</li><li>دوار</li><li>طنين في الأذن</li><li>نُعاس</li><li>خفقان</li><li>ارتفاع ضغط الدم</li><li>الشعور بالإحمرار</li><li>دم في البراز</li><li>تقرحات في المعدة</li><li>أعراض التهاب المريء (أنبوب مرور الطعام) تشمل حرقة المعدة وصعوبة البلع</li><li>التهاب الفم أو تقرحات بالفم</li><li>تغيرات في فحوصات وظائف الكلى أو الكبد</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة: قد تؤثر فيما يصل إلى شخص من بين كل 1000 شخص</strong></p><ul dir="rtl"><li>رد فعل تحسسي شديد</li><li>اضطرابات في المزاج</li><li>صعوبة في النوم (أرق)</li><li>كوابيس</li><li>الشعور بالارتباك</li><li>مشاكل في الإبصار مثل تغيم الرؤية</li><li>نوبات ربو</li><li>ألم ناتج عن تمزق جدار المعدة أو الأمعاء</li><li>التهاب المعدة أو القولون</li><li>التهاب الكبد (مشاكل الكبد)</li><li>ردود فعل جلدية شديدة (مثل الطفح، الحمى والنفطات)</li><li>حساسية الجلد للضوء</li><li>الفشل الكلوي</li><li>تم الإبلاغ عن طفح جلدي يمكن أن يكون مهدد للحياة (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي) (أنظر إلى القسم 2).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدا: قد تؤثر فيما يصل إلى شخص من بين كل 10000 شخص</strong></p><ul dir="rtl"><li>حكة وتورم في الجلد</li><li>بقع حمراء مع حكة تشبه الحصبة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير التكرار من البيانات المتاحة.&nbsp; </strong></p><ul dir="rtl"><li>حساسية الجلد للضوء</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث تقرحات بالمعدة. وقد تنزف داخل الأمعاء (مما يتسبب في براز كريه، داكن للغاية)، وفي حالات نادرة يمكن أن تُثقب هذه التقرحات مسببة تجويفاً في جدار الأمعاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحدث هذا في أي وقت وهو مهم بالتحديد لدى كبار السن ونادراً ما يكون مميتاً. إذا ظهرت عليك أي من هذه الأعراض، يجب عليك التواصل مع طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحدث بشكل نادر ردود فعل تحسسية خطيرة مثل الصدمة التأقية. تشمل الأعراض تورم الوجه، الشفتين، اللسان والحلق التي قد تؤدي إلى صعوبات في التنفس. إذا كنت تظن أنك تعاني من رد فعل تحسسي أو شعرت بالتعب أوقف العلاج واطلب المشورة الطبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، يمكن أن يؤثر ميلوكسيكام على خلايا الدم البيضاء مما يضعف مناعتك ضد العدوى. إذا أصبت بعدوى مع أعراض مثل الحمى، مع تدهور سريع في الحالة العامة، أو حمى مع أعراض عدوى موضعية مثل ألم في الرقبة، الحلق، الفم أو صعوبة التبول، يجب استشارة الطبيب على الفور لإجراء اختبار دم لاستبعاد وجود نقص في خلايا الدم البيضاء (ندرة المحببات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن ترتبط بعض الأدوية مثل ميلوكسيكام بزيادة بسيطة في احتمالية حدوث نوبة قلبية (احتشاء عضلة القلب) أو سكتة دماغية.</p><p dir="RTL">&nbsp;</p><p>في حال أصبحت أي من الأعراض الجانبية خطيرة أو ملاحظتك لأي آثار جانبية غير مذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ في مكان جاف عند درجة حرارة أقل من ٣٠&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p>لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ميلوكسيكام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل كبسولة من موڤن ٧.٥ ملغم و١٥ ملغم كبسولات على ٧.٥ ملغم أو ١٥ ملغم ميلوكسيكام؛ على التوالي.</p><p dir="RTL">&nbsp;</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز، سيترات ثلاثي الصوديوم، نشا الذرة، ثاني أكسيد السليكون الغروي وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">موڤن ٧.٥ ملغم كبسولات هي كبسولات لامعة بحجم (٣) معتمة باللون الأخضر-الأبيض المصفر ومطبوع عليها شعار باللون الأسود &quot;141&quot; على الغطاء و&quot;AP&quot; على الجسم، ومعبأة بمسحوق أصفر خالٍ من الشوائب المرئية في أشرطة من كلوريد متعدد الڤينيل/كلوريد متعدد الڤينيليدين- الألومنيوم.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">موڤن ١٥ ملغم كبسولات هي كبسولات لامعة بحجم (٣) معتمة باللون الأزرق-البرتقالي ومطبوع عليها شعار باللون الأسود &quot;142&quot; على الغطاء و&quot;AP&quot; على الجسم، ومعبأة بمسحوق أصفر خالٍ من الشوائب المرئية في أشرطة من كلوريد متعدد الڤينيل/كلوريد متعدد الڤينيليدين- الألومنيوم.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">حجم العبوة: ١٠ كبسولات أو ٣٠ كبسولة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والشركة المصنعة</strong></p><p dir="RTL">الشركة العربية لصناعة الأدوية المساهمة الخاصة</p><p dir="RTL">صندوق بريد ٤٢</p><p dir="RTL">السلط، الأردن</p><p dir="RTL">هاتف: ٣٤٩٢٢٠٠ (٥-٩٦٢) +</p><p dir="RTL">فاكس: ٣٤٩٢٢٠٣&nbsp;(٥-٩٦٢) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul><li dir="RTL">&nbsp; &nbsp; المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul><li dir="RTL">&nbsp; &nbsp; دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ ٢٠٢١/٠٦، رقم النسخة: SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Moven 15 mg Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 15 mg meloxicam.

Excipient with known effect: 
Each capsule contains 86 mg lactose monohydrate. 
Each capsule contains 6.4 mg sodium. 

For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules. 

Size (3) opaque blue-buff polished capsules printed with black logo “142” on the cap and ”AP” on the body, filled with yellow powder free from visible contaminants
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Short-term symptomatic treatment of exacerbations of osteoarthrosis.</p><p>&nbsp;</p><p>Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral use.</p><p>&nbsp;</p><p>The total daily amount should be taken as a single dose, with water or another liquid, during a meal.</p><p>&nbsp;</p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis. &nbsp;</p><p>&nbsp;</p><p><u>Exacerbations of osteoarthrosis:</u> 7.5 mg/day.</p><p>&nbsp;</p><p>If necessary, in the absence of improvement, the dose may be increased to 15 mg/day (two capsules of 7.5 mg or 1 capsule of 15 mg).</p><p><em>&nbsp;</em></p><p><u>Rheumatoid arthritis, ankylosing spondylitis:</u> 15 mg/day (two capsules of 7.5 mg or 1 capsule of 15 mg) (see also &ldquo;special populations&rdquo;).</p><p>&nbsp;</p><p>According to the therapeutic response, the dose may be reduced to 7.5 mg/day (1 capsule of 7.5 mg).</p><p><strong>&nbsp;</strong></p><p>Do not exceed the dose of 15 mg/day.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly patients and patients with increased risks for adverse reaction (see section 5.2):</em></p><p>The recommended dose for long-term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Renal impairment (see section 5.2):</em></p><p>In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg per day.</p><p>&nbsp;</p><p>No dose reduction is required in patients with mild to moderate renal impairment (i.e. patients with a creatinine clearance of greater than 25 ml/min). (For patients with non-dialysed severe renal failure, see section 4.3).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment (see section 5.2):</em></p><p>No dose reduction is required in patients with mild to moderate hepatic impairment (For patients with severely impaired liver function, see section 4.3).</p><p><em>&nbsp;</em></p><p><em>Children and adolescents:</em></p><p>Meloxicam is contraindicated in children and adolescents aged under 16 years. (see section 4.3).</p><p>&nbsp;</p><p>This medicinal product exists in other strengths, which may be more appropriate.</p><p>&nbsp;</p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Moven is contraindicated in the following situations: 
•	Third trimester of pregnancy (See section 4.6 ‘Fertility, pregnancy and lactation’)
•	Children and adolescents aged under 16 years
•	Hypersensitivity to meloxicam or to one of the excipients, or hypersensitivity to substances with a similar action, e.g. NSAID’s, aspirin. Meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or other NSAID’s
•	Severely impaired liver function
•	Non-dialysed severe renal failure
•	Gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders
•	History of gastro-intestinal bleeding or perforation, related to previous NSAIDs therapy
•	Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding)
•	Severe heart failure.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2 and GI and cardiovascular risks below).</p><p>The recommended maximum daily dose should not be exceeded in case of insufficient therapeutic effect, nor should an additional NSAID be added to the therapy because this may increase the toxicity while therapeutic advantage has not been proven. In the absence of improvement after several days, the clinical benefit of the treatment should be reassessed. The use of Meloxicam, with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.</p><p>&nbsp;</p><p>Any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with meloxicam. Attention should routinely be paid to the possible onset of a recurrence in patients treated with Meloxicam and with a past history of this type.</p><p>&nbsp;</p><p>Meloxicam is not appropriate for the treatment of patients requiring relief from acute pain.</p><p>&nbsp;</p><p>In the absence of improvement after several days, the clinical benefit of the treatment should be reassessed.</p><p>&nbsp;</p><p>Any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with meloxicam. Attention should routinely be paid to the possible onset of a recurrence in patients treated with meloxicam and with a past history of this type.</p><p>&nbsp;</p><p>Meloxicam is not appropriate for the treatment of patients requiring relief from acute</p><p>pain.</p><p>&nbsp;</p><p>In the absence of improvement after several days, the clinical benefit of the treatment</p><p>should be reassessed.</p><p>Any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to</p><p>ensure their total cure before starting treatment with meloxicam. Attention should</p><p>routinely be paid to the possible onset of a recurrence in patients treated with</p><p>meloxicam and with a past history of this type.</p><p>&nbsp;</p><p><strong>Gastrointestinal Effects</strong></p><p>GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.</p><p>&nbsp;</p><p>The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforations (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available.</p><p>&nbsp;</p><p>Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and section 4.5).</p><p>&nbsp;</p><p>Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.</p><p>&nbsp;</p><p>Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as heparin as curative treatment or given in geriatrics, oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as aspirin or other non-steroidal anti-inflammatory drugs, including acetylsalicylic acid given at anti-inflammatory doses (&ge; 1g as single intake or &ge; 3g as total daily amount) (see section 4.5).</p><p>&nbsp;</p><p>When GI bleeding or ulceration occurs in patients receiving Meloxicam, the treatment should be withdrawn.</p><p>&nbsp;</p><p>NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn&rsquo;s disease) as these conditions may be exacerbated (see section 4.8 &ndash; undesirable effects).</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Cardiovascular and cerebrovascular effects</strong></p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. Clinical monitoring of blood pressure for patients at risk is recommended at baseline and especially during treatment initiation with Meloxicam.</p><p>&nbsp;</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs including meloxicam (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke)<em>. </em>There are insufficient data to exclude such a risk for meloxicam.</p><p>&nbsp;</p><p>Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with meloxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p>&nbsp;</p><p><strong>Skin reactions</strong></p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens- Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment.</p><p>&nbsp;</p><p>Meloxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>&nbsp;</p><p>Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with the use of Meloxicam.</p><ul><li>Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment.</li><li>If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Meloxicam treatment should be discontinued.</li><li>The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis.</li><li>If the patient has developed SJS or TEN with the use of Meloxicam, Meloxicam must not be re-started in this patient at any time.</li></ul><p><strong><em>&nbsp;</em></strong></p><p><strong>Parameters of liver and renal function</strong></p><p>As with most NSAIDs, occasional increases in serum transaminase levels, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen and other laboratory disturbances, have been reported. The majority of these instances involved transitory and slight abnormalities.</p><p>&nbsp;</p><p>Should any such abnormality prove significant or persistent, the administration of Meloxicam should be stopped and appropriate investigations undertaken.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Functional renal failure</strong></p><p>NSAIDs, by inhibiting the vasodilating effect of renal prostaglandins, may induce a functional renal failure by reduction of glomerular filtration. This adverse event is dose-dependant. At the beginning of the treatment, or after dose increase, careful monitoring of diuresis and renal function is recommended in patients with the following risk factors:</p><ul><li>Elderly</li><li>Concomitant treatments such as ACE inhibitors, angiotensin-II antagonists, sartans, diuretics (see section 4.5.)</li><li>Hypovolaemia (whatever the cause)</li><li>Congestive heart failure</li><li>Renal failure</li><li>Nephrotic syndrome</li><li>Lupus nephropathy</li><li>Severe hepatic dysfunction (serum albumin &lt;25 g/l or Child-Pugh score &gt;10)</li></ul><p>&nbsp;</p><p>&nbsp;In rare instances, NSAIDs may be the cause of interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Sodium, potassium and water retention</strong></p><p>Induction of sodium, potassium and water retention and interference with the natriuretic effects of diuretics may occur with NSAIDs. Furthermore, a decrease of the antihypertensive effect of antihypertensive drugs can occur (see section 4.5).</p><p>&nbsp;</p><p>Consequently, oedema, cardiac failure or hypertension may be precipitated or exacerbated in susceptible patients as a result. Clinical monitoring is therefore necessary for patients at risk (see section 4.2 and 4.3).</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Hyperkalaemia</strong></p><p>Hyperkalaemia can be favoured by diabetes or concomitant treatment known to increase kalaemia (see section 4.5). Regular monitoring of potassium values should be performed in such cases.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Other warnings and precautions</strong></p><p>Adverse reactions are often less well tolerated in elderly, fragile or weakened individuals, who therefore require careful monitoring. As with other NSAIDs, particular caution is required in the elderly, in whom renal, hepatic and cardiac functions are frequently impaired. The elderly have an increased frequency of adverse events to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2).</p><p>&nbsp;</p><p>Meloxicam, as any other NSAID may mask symptoms of an underlying infectious disease.</p><p>&nbsp;</p><p>The use of Meloxicam, as with any drug known to inhibit cyclooxygenase/prostaglandin syntheses, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of Meloxicam should be considered.</p><p>&nbsp;</p><p><strong>Excipients</strong></p><p>Moven contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>Moven contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p><strong>Pharmacodynamic Interactions:</strong></p><p><u>Other non steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicyclic acid &ge; 3g/d:</u></p><p>Combination (see section 4.4) with other non steroidal anti-inflammatory drugs, including acetylsalicylic acid given at anti-inflammatory doses (&ge; 1g as single intake or &ge; 3g as total daily amount) is not recommended. Administration of several NSAIDs together may increase the risk of gastrointestinal ulcers and bleeding, via a synergistic effect.</p><p>&nbsp;</p><p><u>Corticosteroids (e.g. Glucocorticoids):</u></p><p>The concomitant use with corticosteroids requests caution because of an increased risk of bleeding or gastrointestinal ulceration.</p><p>&nbsp;</p><p><u>Anticoagulants or heparin administered in geriatrics or at curative doses:</u></p><p>Considerably increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal mucosa. NSAIDs may enhance the effects of anticoagulants, such as warfarin (see section 4.4). The concomitant use of NSAIDs and anticoagulants or heparin administered in geriatrics or at curative dose is not recommended (see section 4.4).</p><p>&nbsp;</p><p>In remaining cases of heparin use caution is necessary due to an increased bleeding risk.</p><p>Careful monitoring of the INR is required if it proves impossible to avoid such combination.</p><p>&nbsp;</p><p><u>Thrombolytics and antiplatelet drugs:</u></p><p>Increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal mucosa.</p><p>&nbsp;</p><p><u>Selective serotonin reuptake inhibitors (SSRIs):</u></p><p>Increased risk of gastrointestinal bleeding.</p><p>&nbsp;</p><p><u>Diuretics, ACE inhibitors and Angiotensin-II Antagonists:</u></p><p>NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin-II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter (see also section 4.4).</p><p>&nbsp;</p><p><u>Other antihypertensive drugs (e.g. Beta-blockers):</u></p><p>As for the latter, a decrease of the antihypertensive effect of beta-blockers (due to inhibition of prostaglandins with vasodilatory effect) can occur.</p><p>&nbsp;</p><p><u>Calcineurin inhibitors (e.g. cyclosporin, tacrolimus):</u></p><p>Nephrotoxicity of cyclosporin may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combined treatment renal function is to be measured. A careful monitoring of the renal function is recommended, especially in the elderly.</p><p>&nbsp;</p><p><u>Intrauterine devices</u></p><p>A decrease of the efficacy of intrauterine devices by NSAIDs has been previously reported but needs further confirmation.</p><p>&nbsp;</p><p><strong>Pharmacokinetic Interactions (Effect of meloxicam on the pharmacokinetics of other drugs):</strong></p><p><u>Lithium:</u></p><p>NSAIDs have been reported to increase blood lithium levels (via decreased renal excretion of lithium), which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended (see section 4.4). If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of Meloxicam treatment.</p><p>&nbsp;</p><p><u>Methotrexate:</u></p><p>NSAIDs can reduce the tubular secretion of methotrexate thereby increasing the plasma concentrations of methotrexate. For this reason, for patients on high dosages of methotrexate (more than 15 mg/week) the concomitant use of NSAIDs is not recommended (see section 4.4).</p><p>&nbsp;</p><p>The risk of an interaction between NSAID preparations and methotrexate, should be considered also in patients on low dosage of methotrexate, especially in patients with impaired renal function. In case combination treatment is necessary blood cell count and the renal function should be monitored. Caution should be taken in case both NSAID and methotrexate are given within 3 days, in which case the plasma level of methotrexate may increase and cause increased toxicity.</p><p>&nbsp;</p><p>Although the pharmacokinetics of methotrexate (15 mg/week) were not relevantly affected by concomitant meloxicam treatment, it should be considered that the haematological toxicity of methotrexate can be amplified by treatment with NSAID drugs (see above). (see section 4.8).</p><p>&nbsp;</p><p><strong>Pharmacokinetic Interactions (Effect of other drugs on the pharmacokinetics of Meloxicam):</strong></p><p><u>Cholestyramine:</u></p><p>Cholestyramine accelerates the elimination of meloxicam by interrupting the enterohepatic circulation so that clearance for meloxicam increases by 50% and the half-life decreases to 13&plusmn;3 hrs. This interaction is of clinical significance.</p><p>&nbsp;</p><p>No clinically relevant pharmacokinetic drug-drug interactions were detected with respect to the concomitant administration of antacids, cimetidine and digoxin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been</p><p>reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.</p><p>&nbsp;</p><p>During the first and second trimester of pregnancy, meloxicam should not be given unless clearly necessary. If meloxicam is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.</p><p>&nbsp;</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may</p><p>expose the foetus to:</p><ul><li>Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);</li><li>renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;</li></ul><p>&nbsp;</p><p>The mother and the neonate, at the end of pregnancy, to:</p><ul><li>possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.</li><li>inhibition of uterine contractions resulting in delayed or prolonged labour.</li></ul><p>&nbsp;</p><p>Consequently, Meloxicam is contraindicated during the third trimester of pregnancy.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>While no specific experience exists for meloxicam, NSAIDs are known to pass into mother&rsquo;s milk. Administration therefore is not recommended in women who are breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no specific studies on the ability to drive and use machiney. However, on the basis of the pharmacodynamic profile and reported adverse drug reactions, meloxicam is likely to have no or negligible influence on these abilities. However, when visual disturbances or drowsiness, vertigo or other central nervous system disturbances occur, it is advisable to refrain from driving and operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a)&nbsp; Summary of the safety profile</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).</p><p>&nbsp;</p><p>Oedema, hypertension, and cardiac failure, have been reported in association with NSAID</p><p>treatment.</p><p>&nbsp;</p><p>The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&rsquo;s disease (see section 4.4 - Special warnings and precautions for use) have been reported following administration. Less frequently, gastritis has been observed.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (see section 4.4).</p><p>&nbsp;</p><p>The frequencies of adverse drug reactions given below are based on corresponding occurrences of reported adverse events in 27 clinical trials with a treatment duration of at least 14 days. The information is based on clinical trials involving 15197 patients who have been treated with daily oral doses of 7.5 or 15 mg meloxicam capsules over a period of up to one year.</p><p>&nbsp;</p><p>Adverse drug reactions that have come to light as a result of reports received in relation to administration of the marketed product are included.</p><p>&nbsp;</p><p>Adverse reactions have been ranked under headings of frequency using the following</p><p>convention:</p><p>Very common (&gt; 1/10); common (&gt; 1/100 to &lt; 1/10); uncommon (&gt; 1/1,000 to &lt; 1/100); rare (&gt; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>b)&nbsp; Tabulated list of adverse reactions</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p>Blood and lymphatic system disorders</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Anaemia</p></td></tr><tr><td><p>Rare</p></td><td><p>Blood count abnormal (including differential white cell count), leukopenia, thrombocytopenia</p></td></tr><tr><td><p>Very rare</p></td><td><p>Cases of agranulocytosis have been reported</p><p>(see section c)</p></td></tr><tr><td colspan="2"><p>Immune system disorders</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Allergic reactions other than anaphylactic or</p><p>anaphylactoid reactions</p></td></tr><tr><td><p>Not known</p></td><td><p>Anaphylactic reaction, anaphylactoid</p><p>reactions</p></td></tr><tr><td colspan="2"><p>Psychiatric disorders</p></td></tr><tr><td><p>Rare</p></td><td><p>Mood altered, nightmares</p></td></tr><tr><td><p>Not known</p></td><td><p>Confusional state, disorientation</p></td></tr><tr><td colspan="2"><p>Nervous system disorders</p></td></tr><tr><td><p>Common</p></td><td><p>Headache</p></td></tr><tr><td><p>Uncommon&nbsp;&nbsp;&nbsp;</p></td><td><p>Dizziness, somnolence</p></td></tr><tr><td colspan="2"><p>Eye disorders</p></td></tr><tr><td><p>Rare</p></td><td><p>Visual disturbance including blurred vision;</p><p>conjunctivitis</p></td></tr><tr><td colspan="2"><p>Ear and labyrinth disorders</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Vertigo</p></td></tr><tr><td><p>Rare</p></td><td><p>Tinnitus</p></td></tr><tr><td colspan="2"><p>Cardiac disorders</p></td></tr><tr><td><p>Rare</p></td><td><p>Palpitations</p></td></tr><tr><td><p>Not known</p></td><td><p>Cardiac failure has been reported in</p><p>association with NSAID treatment</p></td></tr><tr><td><p>Very rare</p></td><td><p>Risk of arterial thrombotic events (for example, myocardial infarction or stroke)</p></td></tr><tr><td colspan="2"><p>Vascular disorders</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Blood pressure increased (see section 4.4),</p><p>flushing</p></td></tr><tr><td colspan="2"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td><p>Rare</p></td><td><p>Asthma in individuals allergic to aspirin or</p><p>other NSAIDs</p></td></tr><tr><td colspan="2"><p>Gastrointestinal disorders</p></td></tr><tr><td><p>Very common</p></td><td><p>Gastrointestinal disorders such as dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhoea</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Occult or macroscopic gastrointestinal haemorrhage*, stomatitis, gastritis, eructation</p></td></tr><tr><td><p>Rare</p></td><td><p>Colitis, gastroduodenal ulcer, oesophagitis</p></td></tr><tr><td><p>Very rare</p></td><td><p>Gastrointestinal perforation*</p></td></tr><tr><td><p>Not Known</p></td><td><p>Pancreatitis</p></td></tr><tr><td colspan="2"><p>Hepatobiliary disorders</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Liver function disorder (e.g. raised transaminases or bilirubin)</p></td></tr><tr><td><p>Very rare</p></td><td><p>Hepatitis</p></td></tr><tr><td colspan="2"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Angioedema, pruritus, rash</p></td></tr><tr><td><p>Rare</p></td><td><p>Stevens-Johnson syndrome, toxic epidermal</p><p>necrolysis, urticaria</p></td></tr><tr><td><p>Very rare</p></td><td><p>Dermatitis bullous, erythema multiforme</p></td></tr><tr><td><p>Not known</p></td><td><p>Photosensitivity reaction</p></td></tr><tr><td colspan="2"><p>Renal and urinary disorders</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Sodium and water retention, hyperkalaemia</p><p>(see sections 4.4 and 4.5), renal function test</p><p>abnormal (increased serum creatinine and/or</p><p>serum urea)</p></td></tr><tr><td><p>Very rare</p></td><td><p>Acute functional renal failure in patients with</p><p>risk factors (see section 4.4)</p></td></tr><tr><td colspan="2"><p>General disorders and administration site conditions</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Oedema including oedema of the lower limbs</p></td></tr></tbody></table><p>*Gastrointestinal haemorrhage, ulceration or perforation may sometimes be severe and potentially fatal, especially in elderly (see section 4.4).</p><p>&nbsp;</p><p>c) Description of selected adverse reactions</p><p>Very rare cases of agranulocytosis have been reported in patients treated with meloxicam and</p><p>other potentially myelotoxic drugs (see section 4.5).</p><p>&nbsp;</p><p>d) Adverse reactions which have not been observed yet in relation to the product, but which</p><p>are generally accepted as being attributable to other compounds in the class</p><p>&nbsp;</p><p>Organic renal injury probably resulting in acute renal failure: very rare cases of interstitial</p><p>nephritis, acute tubular necrosis, nephrotic syndrome, and papillary necrosis have been</p><p>reported (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse events:</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting systems applied at their countries via: &nbsp;</p><ul><li><strong>Saudi Arabia </strong></li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li><strong>Other GCC States </strong></li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur.</p><p>&nbsp;</p><p>Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs and may occur following an overdose.</p><p>&nbsp;</p><p>Patients should be managed with symptomatic and supportive care following an NSAID overdose. Accelerated removal by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Non-Steroidal Anti-inflammatory and antirheumatic products (Oxicams), ATC Code: M01AC06.</p><p>&nbsp;</p><p>Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with anti-inflammatory, analgesic and antipyretic properties.</p><p>&nbsp;</p><p>The anti-inflammatory activity of meloxicam has been proven in classical models of inflammation. As with other NSAIDs, its precise mechanism of action remains unknown. However, there is at least one common mode of action shared by all NSAIDs (including meloxicam): inhibition of the biosynthesis of prostaglandins, known inflammation mediators.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Meloxicam is well absorbed from the gastrointestinal tract, which is reflected by a high absolute bioavailability of 89% following oral administration (capsule). Tablets, oral suspension and capsules were shown to be bioequivalent.</p><p>&nbsp;</p><p>Following single dose administration of meloxicam, mean maximum plasma concentrations are achieved within 2 hours for the suspension and within 5-6 hours with solid oral dosage forms (capsules and tablets).</p><p>&nbsp;</p><p>With multiple dosing, steady state conditions were reached within 3 to 5 days. Once daily dosing leads to drug plasma concentrations with a relatively small peak-trough fluctuation in the range of 0.4-1.0 &mu;g/ml for 7.5 mg doses and 0.8 &ndash; 2.0 &mu;g/ml for 15 mg doses, respectively (C<sub>min</sub> and C<sub>max</sub> at steady state, respectively). Maximum plasma concentrations of meloxicam at steady state are achieved within five to six hours for the tablet, capsule and the oral suspension, respectively. Continuous treatment for periods of more than one year results in similar drug concentrations to those seen once steady state is first achieved. Extent of absorption for meloxicam following oral administration is not altered by concomitant food intake.</p><p>&nbsp;</p><p><strong>Distribution </strong></p><p>Meloxicam is very strongly bound to plasma proteins, essentially albumin (99%).</p><p>&nbsp;</p><p>Meloxicam penetrates into synovial fluid to give concentrations approximately half of those in plasma. Volume of distribution is low, on average 11 litres. Interindividual variation is the order of 30-40%.</p><p>&nbsp;</p><p><strong>Biotransformation</strong></p><p>Meloxicam undergoes extensive hepatic biotransformation. Four different metabolites of meloxicam were identified in urine, which are all pharmacodynamically inactive. The major metabolite, 5&rsquo;-carboxymeloxicam (60% of dose), is formed by oxidation of an intermediate metabolite 5&rsquo;-hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies suggest that CYP 2C9 plays an important role in this metabolic pathway, with a minor contribution from the CYP 3A4 isoenzyme. The patient&rsquo;s peroxidase activity is probably responsible for the other two metabolites, which account for 16% and 4% of the administered dose respectively.</p><p><strong>&nbsp;</strong></p><p><strong>Elimination</strong></p><p>Meloxicam is excreted predominantly in the form of metabolites and occurs to equal extents in urine and faeces. Less than 5% of the daily dose is excreted unchanged in faeces, while only traces of the parent compound are excreted in urine.</p><p>The mean elimination half-life is about 20 hours. Total plasma clearance amounts on average 8 ml/min.</p><p>&nbsp;</p><p><strong>Linearity/non-linearity</strong></p><p>Meloxicam demonstrates linear pharmacokinetics in the therapeutic dose range of 7.5 mg and 15 mg following per oral or intramuscular administration.</p><p>&nbsp;</p><p><strong>Specific Populations</strong></p><p><em>Hepatic/renal Insufficiency:</em></p><p>Neither hepatic, mild nor moderate renal insufficiency has a substantial effect on meloxicam pharmacokinetics. In terminal renal failure, the increase in the volume of distribution may result in higher free meloxicam concentrations, and a daily dose of 7.5 mg must not be exceeded (See section 4.2).</p><p><em>&nbsp;</em></p><p><em>Elderly:</em></p><p>Mean plasma clearance at steady state in elderly subjects was slightly lower than that reported for younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicological profile of meloxicam has been found in preclinical studies to be identical to that of NSAIDs: gastrointestinal ulcers and erosions, renal papillary necrosis at high doses during chronic administration in two animal species.</p><p>&nbsp;</p><p>Oral reproductive studies with meloxicam in the rat have shown a decrease of ovulations and&nbsp;inhibition of implantations and embryotoxic effects (increase of resorptions) at maternotoxic&nbsp;dose levels at 1 mg/kg and higher. Studies of toxicity on reproduction in rats and rabbits did&nbsp;not reveal teratogenicity up to oral doses of 4 mg/kg in rats and 80 mg/kg in rabbits.</p><p>&nbsp;</p><p>The affected dose levels exceeded the clinical dose (7.5 &ndash; 15 mg) by a factor of 10 to 5-fold on&nbsp;a mg/kg dose basis (75 kg person). Fetotoxic effects at the end of gestation, shared by all prostaglandin synthesis inhibitors, have been described. No evidence has been found of any mutagenic effect, either in vitro or in vivo. No carcinogenic risk has been found in the rat and mouse at doses far higher than those used clinically.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trisodium citrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maize starch</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colloidal silicone dioxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a dry place below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyvinyl chloride/polyvinylidene chloride- aluminum blisters.</p><p><strong>&nbsp;</strong></p><p>Pack sizes: 10 and 30 Capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Arab Pharmaceutical Manufacturing PSC
P.O. Box 42
Sult, Jordan
Tel: + (962-5)3492200
Fax: + (962-5)3492203 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                29 June 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>